Novavax Selection of IDBS PIMS for Data Management

This case study outlines Novavax's decision to implement IDBS PIMS as their process information management system. Novavax, a biotechnology company focused on vaccine development, faced challenges in managing complex data related to their COVID-19 vaccine candidate, NVX-CoV2373. The urgency of scaling up manufacturing and ensuring compliance with regulatory standards drove the need for a robust data management solution. The evaluation process highlighted the importance of deployment speed, user acceptance, and CMO collaboration. Novavax reported that PIMS was deployed in less than a week, allowing them to fast-track their data infrastructure. Key benefits expected from PIMS include accelerated tech transfer post-trials and adherence to compliance requirements, particularly concerning FDA data integrity standards. The case study emphasizes the critical role of effective data management in supporting Novavax's operational needs during a pivotal time in their vaccine development efforts.